BRUSSELS, June 18 /PRNewswire-FirstCall/ --The first data to show that Neupro® (rotigotine transdermal system) significantly improved wellbeing and daily activities ...

UCB announced that Neupro (rotigotine transdermal system) is now available as a once-daily patch for the treatment of signs and symptoms of early and advanced stage idiopathic Parkinson’s disease (PD) ...

Neupro® (Rotigotine Transdermal System) is approved to treat the signs and symptoms of early and advanced stage idiopathic Parkinson's disease and moderate-to-severe primary restless legs syndrome ...

Latest safety and efficacy results for rotigotine in the treatment of moderate to severe restless legs syndrome presented at major North American neurology congress Brussels (Belgium), 13 April 2010, ...

Neupro (rotigotine) is a prescription skin patch used to treat Parkinson’s disease and restless legs syndrome in adults. Neupro has interactions with other drugs and alcohol. For example, it can ...

UCB has already made progress in reformulation and remains committed to bringing Neupro® to U.S. patients suffering from Parkinson's disease and Restless Leg Syndrome Brussels (Belgium) - April 23, ...

ATLANTA, Dec. 13 /PRNewswire/ -- UCB announced today that the supplemental New Drug Application (sNDA) for the use of Neupro(R) as adjunctive therapy with levodopa in adult patients with ...

UCB announced that the FDA has approved Neupro (rotigotine transdermal system) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson’s disease (PD) and as a treatment for ...